Biohaven Pharmaceutical Holding Co Ltd (BHVN) - Total Assets
Based on the latest financial reports, Biohaven Pharmaceutical Holding Co Ltd (BHVN) holds total assets worth $451.45 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BHVN book value for net asset value and shareholders' equity analysis.
Biohaven Pharmaceutical Holding Co Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's total assets have evolved over time, based on quarterly financial data.
Biohaven Pharmaceutical Holding Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Biohaven Pharmaceutical Holding Co Ltd's total assets of $451.45 Million consist of 81.6% current assets and 18.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.40 Million | 4.1% |
| Goodwill | $1.39 Million | 0.3% |
Asset Composition Trend (2017–2025)
This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biohaven Pharmaceutical Holding Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biohaven Pharmaceutical Holding Co Ltd's current assets represent 81.6% of total assets in 2025, a decrease from 93.0% in 2017.
- Cash Position: Cash and equivalents constituted 50.9% of total assets in 2025, down from 89.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 4.1% of total assets.
Biohaven Pharmaceutical Holding Co Ltd Competitors by Total Assets
Key competitors of Biohaven Pharmaceutical Holding Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Biohaven Pharmaceutical Holding Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.18 | 3.49 | 0.21 |
| Quick Ratio | 3.18 | 3.49 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $252.40 Million | $384.25 Million | $-313.29 Million |
Biohaven Pharmaceutical Holding Co Ltd - Advanced Valuation Insights
This section examines the relationship between Biohaven Pharmaceutical Holding Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.22 |
| Latest Market Cap to Assets Ratio | 3.30 |
| Asset Growth Rate (YoY) | -26.6% |
| Total Assets | $451.45 Million |
| Market Capitalization | $1.49 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Biohaven Pharmaceutical Holding Co Ltd's assets at a significant premium (3.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Biohaven Pharmaceutical Holding Co Ltd's assets decreased by 26.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)
The table below shows the annual total assets of Biohaven Pharmaceutical Holding Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $451.45 Million | -26.61% |
| 2024-12-31 | $615.11 Million | +19.85% |
| 2023-12-31 | $513.21 Million | -22.45% |
| 2022-12-31 | $661.78 Million | +365.84% |
| 2021-12-31 | $142.06 Million | +27.41% |
| 2020-12-31 | $111.50 Million | -67.61% |
| 2019-12-31 | $344.26 Million | +18.71% |
| 2018-12-31 | $290.01 Million | +97.44% |
| 2017-12-31 | $146.89 Million | -- |
About Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more